Fasting-mimicking diet with chemo-immunotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a special low-calorie diet (called a fasting-mimicking diet) to standard chemotherapy and immunotherapy can help treat triple-negative breast cancer before surgery. It aims to see if this combination makes the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been diagnosed with triple-negative or near-triple-negative breast cancer, and the tumor is at least 2 cm or has spread to lymph nodes.
- You have not had any prior cancer treatment like chemotherapy, radiation, or targeted therapy.
- You are able to follow a special diet plan and all study procedures.
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You do not have diabetes that requires medication (except metformin), and you have not lost a lot of weight unintentionally recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special low-calorie diet that mimics fasting can make chemotherapy more effective for people with hormone-receptor-positive breast cancer. If you qualify, you would follow this diet for a few days before and during your chemo cycles.
This study tests if a special diet that mimics fasting can help reduce side effects from hormone therapy (aromatase inhibitors) in women with breast cancer. The diet is a low-calorie meal plan designed to lower cholesterol and improve well-being.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.